With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Piper Sandler lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $533 from $535 and keeps an Overweight rating on the shares ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
Verywell Health on MSN1d
New FDA-Approved Painkiller Is a Safer Alternative to OpioidsThe FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.
The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...
If the drug is approved by the US Food and Drug Administration for the treatment of acute pain in January as expected, the ...
Investor's Business Daily on MSN1d
Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid PainkillerVertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.
Vertex Minerals Limited (ASX:VTX) (OTCMKTS:VTXXF) is pleased to announce an update on the Reward <a target=_blank href= ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback